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Management of Cardiovascular Diseases in the Elderly
CHEUK-MAN YU AND CHU-PAK LAU
From Division of Cardiology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong
Kong

Introduction
Ageing of population is one of the major social
and health burdens in most of the afferent countries. In
particular, cardiovascular disease is prevalent in elderly,
which contributes to major morbidity and mortality. In
fact, most of the cardiac diseases are more common
with increasing age, such as hypertension, ischaemic
heart disease, congestive heart failure and cardiac
arrhythmias. It is not uncommon for a general physician
to see elderly patients with some form of cardiovascular
disease in daily practice. In order to administer the most
appropriate and specific therapy to these diseases in
elderly patients, understanding the physiological
changes of human senescence, as well as approach to
investigation and management is important.

Cardiovascular Changes in Ageing
Ageing is associated with progressive and
extensive changes in cardiovascular structures and
function, which may affect the pattern and course and
possibly outcome of cardiovascular diseases. There are
structural changes occur in the myocardium, heart
valves as well as vessels (Table 1). In the heart,
myocardial mass increases with age at a rate of about 1
gram/year together with increases in left ventricular wall
thickness caused by myocyte hypertrophy.1,2 The left
ventricular hypertrophy is explained by the increased
in afterload secondary to raised vessel stiffness3 as well
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as a response to myocyte loss due to apoptosis.4 Besides,
there is progressive accumulation of matrix tissue in
the cardiac interstitium, namely collagen subtypes (in
particular type I and III collagen fibrils) 5,6 and
fibronectin.7 These two factors summatively contribute
to the progressive decrease in chamber compliance and
subsequently development of diastolic dysfunction
which is an important cause of heart failure in geriatric
population.8 Similarly, the vascular stiffness is increased
due to the deposition of collagen and other connective
tissue in the media and especially adventitia of the
medium and large size arteries. 9 The increased
impedence to flow also partially contributes to the
development of left ventricular hypertrophy. Other
structural changes include the degeneration of sinus
node and decrease in number of conducting cells in the
conduction system of the heart. The cardiac valves
become thickened especially the left sided ones and the
valvular circumference are also increased.10 In the
anterior mitral leaflet, nodular thickening of the free
edges with lipid deposition occurs, whereas annular
calcification, diffuse opacification of the leaflet,
ballooning deformity and small scarring are found in
the posterior leaflet.11 The change in mitral leaflets is
not uncommonly accompanied by mild degree of mitral
regurgitation.12 In the aortic valves, calcification and
fenestrations develop with ageing.
Functionally, ageing is associated with reduced
catecholamine responsiveness.13 This limits the ability
of the inotropic and chronotropic effect of the heart to
β-adrengeric stimulation such as during stress and
exercise. The heart rate at rest and during exercise is
also decreased as well as the heart rate variability.
However, the systolic function is preserved with normal
left ventricular dimensions.2 As the left ventricular
compliance is decreased, diastolic pressure increases.
This causes symptoms of exercise intolerance and
development of diastolic heart failure which is much
more common in elderly than young adults.14
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Table 1. Effect of ageing on the cardiovascular structure and function
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Increased myocardial mass and left ventricular (LV) wall thickness
Increased deposition of extracellular matrix
Decreased LV compliance
Decreased early diastolic filling and increased late diastolic filling
Decreased left ventricular cavity size
Increased left atrial size
Increased contraction and relaxation time with decreased heart rate (both at rest and during exercise)
Decreased heart rate variability
Decreased α-adrenergic receptors in LV and decreased responsiveness to β-adrenergic stimulation
Increased valvular fibrosis and thickness
Increased circumference of valves
Mitral annular calcification
Decreased compliance of large and medium-sized arteries
Increased vessel wall thickness and connective tissue
Degeneration of sino-atrial node cells
Decreased number of conducting cells in the AV node

Congestive Heart Failure (CHF)
Epidemiology
Despite efforts in improving the management of
various cardiovascular diseases such as hypertension
and ischaemic heart disease, the incidence and
prevalence of CHF remains increasing. One of the main
reasons in this epidemiological change is the ageing of
the population and improvement in treatment of medical
diseases. Therefore cardiovascular diseases can last long
enough to risk the occurrence of CHF. In fact, both the
prevalence and incidence of CHF are highly agedependent. 15 It is relatively uncommonly in young
adults, and the prevalence increases about two-fold for
each decade older. It is one of the commonest causes
for hospital admission in elderly population.
One of the important terminology is to
differentiate systolic from diastolic dysfunction as the
cause of heart failure. Although both conditions are very
similar in symptomatology, there are aetiological,
prognostic and management differences. Diastolic heart
failure refers to the increased resistance to filling with
increased filling pressure in one or both cardiac
ventricles.16,17 Despite the wide variation in the reported
prevalence, majority of studies reported that 40% of
patients admitted for CHF are due to pure diastolic
dysfunction.18-20 Elderly age is a predictor of diastolic
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heart failure.21 A multicentre study restricted to 623
middle-aged men with chronic heart failure found that
the prevalence of normal systolic function was only
13.3%.22 Wong et al found in a study of 99 consecutive
patients admitted to hospital with heart failure, 41% of
those >70 years had normal systolic function compared
to only 6% of those <60 years.8

Aetiology
In general, the causes of CHF are similar in
younger and older patients, namely ischaemic heart
disease, hypertension, cardiomyopathies, cardiac
arrhythmias as well as valvular heart diseases, especially
left-sided valvular regurgitation or stenosis. In patients
with ischaemic heart disease, patients survived from
an initial myocardial infarction is a major cause of pump
failure. Occasionally, patients with long-standing
myocardial ischaemia and hibernation also contribute
to systolic dysfunction, which can be improved after
revascularisation.23 Degenerative valvular heart disease
is basically a condition of senescence, though in
developing countries CHF complicated by chronic
rheumatic heart disease is not uncommonly
encountered. Common causes of CHF due to cardiac
arrhythmia in relation to inadequate cardiac output in
elderly population are atrial fibrillation, complete heart
block and tachy-brady-arrhythmias. Other causes of
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CHF include infective endocarditis, myocarditis, and
high out-put failure as seen in chronic anaemia and
thyrotoxicosis.
Diseases which prone to develop diastolic
heart failure include hypertension, 24,25 myocardial
ischaemia,26 left ventricular hypertrophy (LVH) (e.g.
hypertrophic cardiomyopathy, 27 pressure-overload,
aortic stenosis, and salt-loading 28,29 ), myocardial
fibrosis30 and myocardial disease (various causes of
cardiomyopathies and myocardial restriction). 31
Systemic hypertension is also more common in heart
failure with normal ejection fraction, which is at least
twice commoner than those with impaired LV systolic
function.32 Abnormal left ventricular diastolic filling is
a common and early finding in hypertension, even
before any obvious LVH or change in systolic function
develops.33 The development of LVH is also common
in ageing. A study found that LVH was present in 43%
of those >70 years of age by echocardiography,
compared with only 6% for those <30 years of age.34
LVH is an adaptive response to the increased wall stress
initially. However, this leads to impaired relaxation, and
increased susceptibility to hypoxia-induced diastolic
dysfunction35 and increased in passive elasticity of the
ventricular chamber. The result is an upward shift of
diastolic pressure-volume relation, i.e., a higher diastolic
pressure for any increases in left ventricular volume.36
In myocardial ischaemia, reversible diastolic
dysfunction occurs even in the context of normal LV
systolic function as occurring in demand ischaemia.37
This is caused by the accumulation of diastolic
intracellular calcium 38 which impairs ventricular
relaxation by slowing the actin-myosin dissociation and
diastolic pressure is raised as a result.39 Ageing itself is
an independent cause of diastolic dysfunction. The
declines in left ventricular diastolic function with
increasing age is related to the increased chamber
stiffness. This change can be explained by structural
changes such as increased interstitial collagen content
in the myocardium 40 as well as impaired active
relaxation due to reduced calcium ion sequestration into
the sarcoplasmic reticulum.41 In addition, increases in
left ventricular mass with ageing may further increase
the passive stiffness of the chamber. Studies have shown
that in normal subjects, ageing alters ventricular
diastolic function independently of LVH or coronary
artery disease with a reduced rate and duration of the
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rapid diastolic filling phase due to increased regional
diastolic asynchrony.42

Diagnosis
Both systolic and diastolic heart failure share
common clinical features including dyspnoea, which
progress to symptoms of orthopnoea and paroxysmal
nocturnal dyspnoea. Acute pulmonary oedema may also
develop. Symptoms of right heart failure include ankle
swelling, abdominal distension due to ascites, and upper
abdominal discomfort due to liver congestion. For
patients with diastolic heart failure, exercise intolerance
is a dominant and early feature.14 Pulmonary congestion
may cause cough and wheezing. The presence of low
cardiac output state results in lethargy and fatigability.
In elderly patients confusion and rarely other mental
manifestation can be the presenting feature. Symptoms
of underlying aetiological factors should also be sought,
such as angina, palpitation or long-standing history of
hypertension.
Physical examination will confirm features of
fluid overload, namely ankle oedema, raised jugular
venous pressure, basal crepitation in the lung, ascites
with congestive hepatomegaly, and not uncommonly
some degree of pleural effusion. Cardiac asthma with
rhonchi and wheeze in a restless and tachypnoeic patient
can be the dominant features. Signs of sympathetic
stimulation include tachycardia and cold extremities.
The reduced cardiac output is manifested as hypotension
and small pulse volume. Chyne-Stokes respiration,
cardiac cachexia or anasarca may occur. Precordial
examination may show signs of cardiomegaly, heart
murmur and gallop rhythm. Physical signs in relation
to aetiology of heart failure should also be sought, such
as heart murmur of valvular lesions or hypertensive
retionpathy.
Important investigations include
electrocardiography, chest roentgenography and
echocardiography. Relevant investigations to diagnose
the cause of heart failure should be considered, such as
exercise tolerance test and coronary angiography for
suspected ischaemic heart disease. In the presence of
LVH in electrocardiogram and relatively normal heart
size on chest roentgenogram one should raise
the suspicion of diastolic heart failure. However,
echocardiography remains the cornerstone to identify the
nature of heart failure as well as its possible aetiology.
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Echocardiography
Echocardiography should be performed to all
patients presented with CHF. M-mode and 2-D
echocardiography is useful to assess the presence and
severity of systolic dysfunction. With the combination
of colour Doppler studies, causes which precipitate heart
failure can be diagnosed such as left ventricular
hypertrophy, regional wall motion abnormalities,
myocardial infarction and aneurysm, valvular stenosis
and regurgitation, mitral annular calcification,
cardiomyopathies and pericardial disease. The
assessment of diastolic function relies on the use of
Doppler echocardiography. By using pulse Doppler
studies, mitral flow velocity curve at diastole can be
constructed. The commonly described pattern of
diastolic dysfunction in diastolic heart failure is
abnormal relaxation pattern, in which the early diastolic
filling is decreased due to delayed relaxation, while
atrial filling fraction and its filling velocity is
increased. 43 This pattern is commonly seen in left
ventricular hypertrophy and ischaemia.44 The other end
of the spectrum is restrictive filling pattern.43 It signifies
elevated left atrial and ventricular diastolic filling
pressure and decreased compliance of the chambers.
This pattern is more commonly seen in patients with
accompanying left ventricular systolic dysfunction.45
Occasionally patients can a "pseudonormal" pattern, with
represent a transition from one end to the other in the
spectrum of severity. This pattern has to be
differentiated from normal flow pattern by interrogation
of pulmonary venous flow profile.46 On the interpretation
of Doppler-derived diastolic indices, it is imperative to
aware of physiological factors which may affect the
measurement even in heart failure patients, such as age,
gender, heart rate and respiration.

Treatment and Prognosis
General measures for the treatment of heart
failure include a low dietary salt intake, oxygen therapy
for the presence of hypoxia and the treatment of underlie
cause, such as thrombolytic therapy for acute
myocardial infarction and anti-arrhythmic agents for
cardiac arrhythmias. The principle of treatment includes
both decrease the preload and afterload. In general, the
afterload should be decreased as much as possible by
reducing the systemic resistance so that the workload
of the heart can be optimally reduced. Agents useful
for preload reduction include diuretics and venodilators
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such as nitrates. Arterial vasodilators as well as
angiotensin converting enzyme inhibitor (ACEI) are
agents of choice to decrease afterload. Loop diuretics
are commonly used for acute fluid overload, and its
dosage should be carefully monitored to avoid excess
dehydration which is especially susceptible in elderly
patients. There is also evidence of secondary
neuroendocrine activation such as activation of reninangiotensin system which might hasten the pathogenic
process of myocardial structural damage.48 For patients
with mild heart failure, a thiazide rather than loop
diuretic can be considered.
ACEI is both an arterial and venodilator, which
reduces both preload and afterload. It also reduces the
circulating and possibly tissue ACE level. It is known
by its ability to lower morbidity and mortality of CHF
in patients with left ventricular systolic dysfunction.49
The exercise tolerance and quality of life is also
improved. Its use should especially be considered in
patients with accompanying diuretics intake or adopted
a low salt diet in whom plasma renin is invariably
activated. Recently, angiotensin II receptor antagonist
(AIIA) is also shown to be effective in reducing
mortality in elderly patients with heart failure due to
systolic dysfunction. 50 Importantly, there is no
significant deterioration of renal function in elderly
population by either ACEI or AIIA.50 On the other hand,
renovascular disease is prevalent in elderly patients and
these agents should be selected with caution. 51
Furthermore, one should aware of first-dose hypotensive
effect of ACEI in elderly and give a lower initial dose
since they have a lower renal clearance, which will be
further exacerbated by the presence of heart failure.52
Beta-blocker has been suggested to be a useful treatment
more than twenty years but has not been accepted until
recently that metoprolol and bisoprolol was shown to
have survival benefit in heart failure in multi-centre
trials (MERIT-HF and CIBIS-II).53,54 In CIBIS-II trial
there was a 32% reduction of mortality by bisoprolol
when compared to placebo, 54 which was 34% in
MERIT-HF trial.53 Other vasodilating beta-blockers
such as celiprolol and carvedilol were also shown to be
at least equally effective in improve symptoms and
exercise capacity.55,56 These agents also improve left
ventricular ejection fraction, but it is only evident after
weeks to months, and an initial deterioration of ejection
fraction should be alerted.57 Therefore the drug should
be started cautiously with an initially low dose with
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close monitoring of hemodynamic status. Digoxin is
particular helpful if CHF is accompanying by fast atrial
fibrillation. It also possesses positive inotropic effect
and sympathoinhibitory effect.58 The benefit of cardiac
glycoside in heart failure symptoms have been proven
by large clinical studies.59 A recent study also confirmed
the survival benefit of amiodarone in heart failure, at
lease in those with fast resting heart rate.60 For patients
with cardiogenic shock, inotropic support should be
considered to improve the cardiac output. Cardiac
transplantation is feasible for elderly patients with
intractable heart failure. Although this choice is less
likely considered for geriatric population, the short-term
survival is proven to be comparable to younger
subjects.61 Other surgical measures include myocardial
reduction surgery, and surgical treatment for underlying
cause such as coronary artery bypass surgery for
ischaemic heart disease and valvular replacement for
valvular cause of heart failure. Another important aspect
of non-medical therapy is the adoption of exercise
training in CHF. Exercise training is useful to improve
peak oxygen consumption, increase exercise capacity
as well as improve quality of life.62,63 The long-term
effect of exercise training and the choice of optimal
exercise protocol remain to be determined by
randomised clinical trials.
For patients with diastolic heart failure as the sole
cause of CHF, ACEI and diuretics are appropriate
choices. In human studies, the use of ACEI has shown
to be able to regress LVH as well as normalise left
ventricular diastolic filling.64 The use of diuretics in
diastolic heart failure should be carefully monitored
against the hydration status. Non-discriminatory use of
diuretics may jeopardise the diastolic filling and
compromise cardiac output since these patients are
preload dependent in order to maintain a normal
diastolic filling.65 Other pharmacological agents which
may be useful for diastolic heart failure include betablocker and calcium channel antagonist. The negative
inotropic and/or chronotropic effect of these agents may
allow more complete diastolic filling. However,
treatment of diastolic dysfunction is still empirical and
clinical trials are needed. The underlying cause for
diastolic heart failure should be sought and treated such
as control of hypertension and revascularisation
procedure for ischaemia-induced diastolic dysfunction.
The prognosis for patients with diastolic heart
failure is more favourable than those with systolic
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failure. The reported annual mortality rate is
considerably variable, which varies from <5% to
>15%.66,67 The presence of ischaemic heart disease
adversely affects the prognosis.20 In contrast, patients
with systolic failure had a much higher mortality.68-70
In Framingham Study the 6-year mortality rate was 82%
and 67% respectively for male and female gender.15 The
prognosis in old-old is particularly worse, and it was
reported that the first year mortality was 63% in
institutionalised elderly of 80 years or older after
diagnosed to have heart failure. 71 In patients with
diastolic heart failure, majority of patients are died of
pump failure while in systolic failure, sudden cardiac
death is also a major cause. 72,73 The presence of
restrictive filling pattern in systolic dysfunction signify
a worst prognosis, independent of age.70,74 Another
newer marker of mortality is the elevation of natriuretic
peptides, especially brain natriuretic peptide.75

Ischaemic Heart Disease
Ischaemic heart disease is a common
cardiovascular disease in the elderly, primarily because
atherosclerosis is a time-dependent process. Although
the incidence is lower in middle age women when
compared to men, the loss of oestrogen protection render
the disease equally prevalent in elderly population.
Indeed, ischaemic heart disease is shown to be
independently increased with age.76 Studies found that
angina occurs in approximately 10% of the population
over 70 years of age. 77 The ageing of population
especially in the afferent countries and the change in
life style towards a higher cholesterol diet in the
developing countries should alert clinicians the increase
in incidence of ischaemic heart disease world-wide. On
the other hand, the mortality of ischaemic heart disease
has been declining in United States,78 which is explained
by the fall in incidence of acute myocardial infarction
(AMI). There is an actual fall in death rate after AMI, as a
result of improvement in medical therapy and monitoring
in coronary care unit. With the advent of thrombolytic
therapy and other supportive measures, the in-patient
mortality of AMI decreased over 80% in the past three
decades.

Clinical Features
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patient with ischaemic heart disease. This range from
stable angina, unstable angina to acute myocardial
infarction. Patients with stable angina typically present
with exertional retrosternal, compressing chest tightness
which radiates to the jaw and arm. Occasionally
decubitus angina occur when the patient is lying down,
which is related to the increase in venous return and
hence ventricular chamber tension, rendering a higher
oxygen demand for the greater stroke volume produced
according to the Frank-Starling law. When there is
angina of increasing frequency, severity or duration, or
angina at rest, unstable angina is then assumed. Not
uncommonly there are co-existing risk factors, which
include cigarette smoking, hypertension, diabetes,
hypercholesterolaemia and a positive family history. For
acute myocardial infarction, elderly patients are less
often presented with chest pain or discomfort, but rather,
features of complications such as dyspnoea due to acute
pulmonary congestion or even oedema, 79 or acute
confusion, syncope or stroke.80 Though a significant
proportion of patients remain complain of chest pain, it
may be perceived as less severe or atypical,81 with less
sweating and occasionally even silent myocardial
infarction. Patients may also present with fatal
arrhythmias which result in sudden cardiac death.

Diagnosis
The diagnosis of angina is largely clinical, though
there may be accompanied evidence of ischaemic
changes in ECG. However, in the elderly, it is not
uncommon to have non-specific resting ST-segment and
T-wave changes which make the correct interpretation
of ischaemic changes difficult. Exercise tolerance test
is indicated for the presence of anginal symptoms,
though the diagnostic accuracy is lower for similar
reasons. The sensitivity and specificity of the test is
especially lowered by the presence of accompanying
musculoskeletal disease which prevent patients to
achieve the target heart rate. Therefore alternative
methods can be considered in this age group such as
dobutamine stress echocardiography or dipyridamole
radionuclide scanning.
For the diagnosis of AMI, the usual diagnostic
triad of chest pain, ST segment elevation at two or more
consecutive leads in ECG and elevation of cardiac
enzymes remain useful. However, because of the high
prevalence of non-specific ST-segment and T-wave
changes in the elderly population, as well as the higher
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incidence of bundle branch block, the diagnosis may
be more difficult especially in the absence of typical
chest pain. 81 Before the implementation of MB
isoenzyme of creatine kinase, the use of creatine kinase
alone to diagnose AMI in elderly has less value because
of the decreased muscle mass in senescence.

Treatment and Prognosis
The aim of treatment for patients with angina is
to decrease the frequency and severity of anginal attacks
so as to improve exercise tolerance and quality of life
of patients. General measures include patient education
about risk factor modification, the prevention of
precipitating factors of angina, and the proper way of
using sublingual nitrate tablets or spray for symptomatic
relief. Life style to be modified include smoking
cessation, adopt a low cholesterol diet and weight
reduction. In elderly, smoking remains a significant risk
factor which is supported by the notion that current
smokers have a higher mortality than ex-smokers and
non-smokers.82 The other risk factors for exacerbation
of atherosclerosis should also be sought and treated such
as medical therapy for co-existing hypertension and
diabetes.
Medical therapy for angina in elderly age differs
little from younger patients. The choice of anti-anginal
drugs include nitrates, beta-blockers and calcium
channel antagonist. Since elderly patients have less lean
body mass and a hence a lower creatinine clearance,
they are more susceptible to side effects of medications.
Drugs should be prescribed with caution, especially the
effect of bradycardia, heart block or precipitation of
heart failure from combined beta-blocker and calcium
channel antagonist. In addition, all these agents are able
to induce hypotension, especially in combination
therapy. It is advisable to start with a lower dose and
titrate against symptoms and side effect. Although antianginal treatment is effective in decreasing symptoms,
they have not been proven to be able to improve longterm prognosis.83 Other adjunctive measures include the
use of aspirin and lipid lowering agent for patients with
hypercholesterolaemia. Peptic ulcer or gastritis is a
relatively common problem in elderly patients taking
aspirin, and other non-prostaglandin dependent
inhibitors of platelets such as ticlopidine or clopidogrel
should be considered.84,85 Recently the use of HMG-Co
A reductase inhibitors (statins) as primary and
secondary prevention has been shown to reduce
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myocardial infarction rate and cardiovascular
mortality.86,87 The safety and effectiveness of statin in
elderly patients has been demonstrated.88
Revascularisation procedure such as
percutaneous transluminal coronary angioplasty
(PTCA) and coronary artery bypass surgery (CABG)
can be considered in selected patients. The elderly
patients represent a high risk group for both CABG and
PTCA,89-91 though others suggest that PTCA is a safer
procedure in geriatric age group with a higher initial
success rate than CABG.92 However, provided that the
overall functional status of the patient is satisfactory,
elderly age should not be the sole reason for exclusion
of aggressive treatment regimens. Not uncommonly,
elderly patients are having more concomitant diseases
which largely jeopardise their quality of life, such as
chronic obstructive pulmonary disease and
musculoskeletal problems. A study found that
octogenarians had a higher frequency of CHF, angina,
and previous MI.93 Compared to young adults with IHD,
elderly patients are more commonly suffered from
multivessel or left mainstem disease. 94 Although
procedure complications increase with age, critical
complications such as MI, reocclusion, CABG and death
were not different from younger age group while
primary procedural success was similar in all strata of
age.93 On the other hand, as similar to medical therapy,
revascularisation procedures have not been shown to
improve survival in patients with stable angina,
especially those with preserved left ventricular systolic
function. Only in the subgroup with severe coronary
disease and impaired left ventricular function that
CABG was found to have a survival benefit. 95
Conversely, those patients with no concomitant illness
and preserved left ventricular function have excellent
prognosis after CABG. A study found that for patients
>70 years the 5-year survival rate of multivessel
angioplasty was the same as CABG after matched for
left ventricular function, though the early morbidity and
mortality was higher in the latter group.96 Therefore
revascularisation procedures should be considered for
symptomatic control especially for those already on
optimal anti-anginal drugs or unable to tolerate the side
effects.
In acute myocardial infarction, close monitoring
in coronary care unit and prompt treatment of
complications such as arrhythmias and heart failure is
the key for improvement of acute survival in the past
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few decades. Agents proven useful to decrease mortality
include early thrombolytic therapy, aspirin, betablocker, and ACEI in those with significant left
ventricular systolic dysfunction. Previously elderly age
was a relative contraindication for thrombolytic therapy
because of the increased risk of intracranial
haemorrhage, especially the use of tissue plasminogen
activator (tPA). In earlier studies, patients over 75 years
age are excluded from thrombolytic therapy in most of
the major clinical trials.97 However, in ISIS-2 which
included all ages for thrombolytic therapy found that
even patients older than 70 years had a survival benefit
of >30% when compared with aspirin therapy.98 Further
trials consistently showed a survival benefit in the older
subgroup. 99 In GUSTO trial, elderly patients were
associated with a higher 30-day mortality and were
associated with higher bleeding complication and
morbidities, though increasing age is confounded by
angiographically more severe coronary artery disease
and higher incidence of co-morbidities.100 However, the
use of accelerated t-PA remained to have survival
benefit. It is prudent to start thrombolytic therapy early,
as the shorter the door-to-needle time, the greater the
survival benefit.99 Aspirin has been proven valuable in
post-myocardial infarction by randomised, large scale
studies.98 A 23% reduction in 5-week mortality was
reported when compared with placebo.98 Similarly, the
use of beta-blocker was able to reduce the first week
mortality by 15%, which is likely a result of decreasing
acute cardiac rupture.101 A reduction of mortality by
beta-blockers was also demonstrated in elderly AMI
patients.102 Angiotensin converting enzyme inhibitors
should also be initiated for patients with evidence of
left ventricular systolic dysfunction, as these agents
demonstrated a uniform reduction in long-term
mortality in large clinical trials.49,103 However, elderly
patients are particularly prone to develop first-dose
hypotension and therefore a smaller initial dose with
close hemodynamic monitoring is advisable.52 Other
medication should be considered include adjunctive
antithrombotic therapy such as intravenous heparin if
accelerated t-PA is given, inotropic support for
cardiogenic shock and anti-anginal medications for
those with accompanying post-infarct angina. Antiarrhythmic therapy should be prescribed for patients
with secondary arrhythmias, though physicians should
aware the negative inotropic property of most antiarrhythmic agents. In elderly patients, the difference in
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drug metabolism in elderly patients from younger adults
may result in unusual side effects such as acute
confusional state after lignocaine infusion. Medical
therapy for optimal risk factor modification is important,
and the use of statins has been shown to reduce
subsequent cardiovascular mortality even for mild to
moderate hypercholesterolaemia.87 Revascularisation
procedures are possible modality of treatment though
it is less commonly performed for elderly than younger
adults. However, for suitable candidates, PTCA or
CABG has a role in post-AMI patients for symptomatic
control. Age is a predictor of restenosis after primary
angioplasty in AMI.104
Cardiac rehabilitation programme also plays an
increasing role in improving the exercise capacity and
the quality of life after AMI, even in elderly patients of
older than 75 years.105 Risk factor modification and
education programmes can also be conducted in the
rehabilitation programme. Exercise training can also
improve oxygen consumption as well as ejection
fraction. The long-term benefit of exercise after AMI
in the post-thrombolytic era need to be evaluated by
further clinical studies. The present data found that
control of risk factors especially diabetes mellitus
and enhancement of exercise capacity important targets
to improve the prognosis for those recruited into the
programme.106
Elderly patients with AMI were shown to have a
significantly higher mortality than younger patients. In
one study, increasing age is an independent risk factor
of early and late mortality,107 while other investigators
found that in AMI patients older than 70 the mortality
was at least 4 times higher than younger patients. 108
However, such a great difference may be partly
confounded by the presence of more severe ischaemic
heart disease as well as more concomitant medical
illness. A recent report explained that the contemporary
approach of more aggressive therapy of AMI increased
its survival rendering more patients survived to the
geriatric age with myocardial scarring, which result in
the subsequent development of heart failure and
associated mortality.109

Valvular Heart Disease
With the improvement in the medical treatment
of various diseases worldwide, more individuals now
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live longer, rendering valvular heart diseases in the
elderly become relatively prevalent. This is especially
important in the developing countries where acute
rheumatic fever is a prevalent cardiovascular disease
in the past decades.

Mitral Stenosis
Mitral stenosis is less being encountered
nowadays especially in the developed countries. Most
of the patients presented in middle-age, though
occasionally later in life. The main aetiology is
rheumatic mitral stenosis, where accompanying mitral
regurgitation is not uncommon. In elderly subjects,
calcification of the mitral leaflets and commissures
frequently occur and pliability of the valve is affected.
Occasionally, mitral stenosis is caused by nonrheumatic mitral annular calcification.110

Clinical Features
The clinical features of mitral stenosis is not
much different from younger adults. Patients can also
be asymptomatic, or present with shortness of breath
or even acute pulmonary oedema. Complications of
mitral stenosis include pulmonary hypertension, acute
pulmonary oedema, atrial fibrillation or
thromboembolism. For patients with sinus rhythm, the
severity of mitral stenosis and elderly age are predictors
of thromboembolism.111 Examination findings include
tapping apex, a load first sound, mid-diastolic rumbling
murmur which may only be heard in left decubitus
position, an opening snap and signs of pulmonary
hypertension. Other findings include a malar flush, atrial
fibrillation and a low cardiac output state.

Diagnosis
In the assessment of mitral stenosis,
electrocardiography will reveal evidence of p-mitrale,
right ventricular hypertrophy, right axis deviation or
atrial fibrillation. Chest roentgenography may show
double atrial shadow, biatrial enlargement, enlargement
of right ventricular silhouette and enlargement of
pulmonary arteries. Acute pulmonary oedema in
addition to pulmonary venous congestion may result
from severe stenosis, which is especially precipitated
by co-existing angina. Calcification of the mitral valve
leaflets may be evident. Echocardiography with Doppler
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studies will confirm the typical doming of the leaflets,
and it is important to assess for the severity of stenosis,
the presence of pulmonary hypertension, atrial
enlargement, mitral regurgitation, and assessment of left
ventricular function. The development of scoring system
is helpful as an objective guideline of outcome after
valvuloplasty, which include the assessment of valvular
mobility, thickness, calcification and subvalvular
involvement.112 The use of pressure half-time is a rather
accurate method to estimate mitral valve area, which
has been shown to correlate well with Gorlin formula
at cardiac catheterisation.113 However, this method is
not accurate in the presence of aortic regurgitation and
immediately after mitral commissurotomy. 114
Transoesophageal echocardiography is particular
helpful for the diagnosis of spontaneous
echocardiographic contrast and atrial appendage
thrombi which are predictors of subsequent
thromboembolic complications. 115,116 Cardiac
catheterisation should be performed if surgical treatment
is contemplated in view of the high prevalence of
ischaemic heart disease in geriatric patients.

found that in mitral stenosis the presence of spontaneous
echo contrast is the major predictor of thromboembolic
complication even a patient is in sinus rhythm,
implicating the important of transesophageal
echocardiography and the commencement of
anticoagulation therapy in this disease group.118

Mitral Regurgitation
With the gradual decline in incidence of acute
rheumatic fever and its sequel, myxomatous
degeneration of mitral valve resulting in mitral
regurgitation and mitral valve proplase become more
prevalent than decades ago.119 Other causes of mitral
regurgitation include ischaemia-induced papillary
muscle dysfunction, organic valvular disease and
cardiomyopathy with secondary dilatation of the mitral
annulus. Calcification of mitral annulus may be
accompanied by some degree of mitral regurgitation.
Causes of acute mitral regurgitation include rupture of
chordae tendineae or torn leaflet secondary to infective
endocarditis.

Management
Management of mitral stenosis depends on the
severity. Mild to moderate stenosis can be managed with
medical therapy such as diuretics with regular
echocardiography to monitor the progression of the
disease. For severe cases, percutaneous transluminal
mitral commissurotomy (PTMC) using Inove balloon
is useful to relieve symptoms and delay or even obviates
the need for valvular replacement.117 This procedure now
replaces close mitral valvotomy. However, in elderly
patients, the result is less satisfactory than younger ones
as they are associated with more severe mitral
calcification and less pliable valves. Open mitral
valvotomy can be considered in those with
accompanying left atrial thrombus in which removal
procedure can be performed in a single operation. Mitral
valve replacement can be considered in those with nonpliable mitral leaflets, severe subvalvular involvement,
or with significant accompanying mitral regurgitation.
Tricuspid annuloplasty can be performed for patients
with pulmonary hypertension with significant secondary
tricuspid regurgitation. Patients with metallic valve
replacement or atrial fibrillation need long-term
anticoagulation therapy to prevent the development of
thromboembolic complications. A recent study also
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Clinical Features
Clinical features of mitral regurgitation depends
on its underlie aetiology and severity. Mild mitral
regurgitation is usually well tolerated by patients, while
more severe disease will cause exercise intolerance due
to pulmonary congestion. The elevation of diastolic
filling pressure will result in diastolic dysfunction and
even diastolic heart failure. Occasionally acute onset
mitral regurgitation will result in acute pulmonary
oedema. Patient may also present with complications
such as atrial fibrillation or heart failure, and the latter
is reported in up to 40% of patients.120 Clinically the
apical impulse is displaced with a holosystolic murmur
on auscultation. The first heart sound can be muffled.
Mitral valve prolapse can present with mid or late
systolic murmur and a mid systolic click. Mitral
regurgitation also at a greater risk of worsening in
geriatric patients. In ischaemic papillary muscle
dysfunction, patients can have mitral regurgitation due
to dyschronised contraction of the papillary muscle
base relative to other regions of the heart resulting
in disturbance of valvular coaptation. Patient may
present with angina or even symptoms of exercise
intolerance.
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Diagnosis
The diagnosis of mitral regurgitation nowadays
rely largely on non-invasive measures such as
echocardiography. Colour Doppler echocardiography
is useful to assess the severity of regurgitation, as well
as the degree of left ventricular and left atrial
enlargement. The assessment of valvular pathology and
systolic function is essential for deciding the necessity
of operative management. Helmcke et al found that the
ratio of the regurgitant jet area relative to the left atrial
area correlated with angiographic severity.121 The use
of transoesophageal echocardiography is particularly
helpful to assess valvular morphology and the presence
of left atrial clot or spontaneous echocardiographic
contrast as in case of mitral stenosis. In addition, the
presence of reversal of systolic forward flow in the
pulmonary vein by Doppler study also implicate severe
mitral regurgitation. It is worth to note that some degree
of mitral regurgitation detected by Doppler
echocardiography is very common in the elderly which
is found in up to half of normal subjects and therefore
the finding should be interpreted with caution.122 Cardiac
catheterisation is also indicated especially for potential
surgical candidates to define the severity of valvular
regurgitation and to detect silent coronary artery disease
in otherwise asymptomatic subjects.

Management
For those who have mild to moderate mitral
regurgitation, medical therapy is preferred, which
consists diuretics, angiotensin converting enzyme
inhibitor or other vasodilators for afterload reduction.
Complications such as atrial fibrillation and heart failure
should be treated promptly. In view of the greater risk
of operation in the elderly than younger patients,123,124
surgery should be considered for symptomatic patients
with severe disease before there is significant left
ventricular dilatation and systolic dysfunction. In
general, mitral valve reconstruction is the preferred
approach than valvular replacement if technically
feasible, which is reported to carry a lower surgical
mortality.125

Mitral Annular Calcification
This is a very common condition in octogenarian
patients, which is found to be more than half of the
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population, with female preponderance. Mitral annular
calcification is associated with conditions such as aortic
sclerosis, mitral valve prolapse, ischaemic heart disease,
and systemic illness such as hypertension and chronic
renal failure. It represents a degenerative process in the
valves, which range from small calcified nodules to
involve the entire valve cusps. Clinically mild to
moderate mitral annular calcification are asymptomatic.
In severe cases, it may present with mitral regurgitation
due to the impaired ability of the mitral annular to reduce
its circumference during systole and the decreased
ability of coaptation, and displacement of mitral leaflets
from their normal anatomic position. Other
manifestations include heart block due to conduction
bundle erosion by the calcification, mitral stenosis or
embolic phenomenon.126 The presence of mitral annular
calcification increases operative difficulties for mitral
valve repair with worsening operative risk.127 Mild to
moderate calcification in general does not require
treatment, and only those with complications need to
be treated accordingly.

Aortic Stenosis
Aortic stenosis is a very common form of valvular
heart disease in the elderly. The most frequently
encountered cause is senile calcific degeneration of the
aortic valves, and hence the incidence rises with
increasing age. At Mayo Clinic, it is reported that aortic
stenosis comprised up to half of the cases referred for
valvular operation in those who are 70 years or older.
Other aetiologies include rheumatic heart disease,128
congenital bicuspid aortic valve with subsequent
calcification and congenital commissural fusion. In
contrast, in senile aortic stenosis, typically the aortic
leaflet is free of commissural fusion, but rather with
nodular calcification within the aortic pockets.129

Clinical Features
Mild aortic stenosis is usually asymptomatic.
Patients with severe disease may have features of
exertional angina and syncopy. The physical signs for
aortic stenosis can be misleading. In elderly subjects,
murmur of aortic sclerosis without significant stenosis
is frequently present. Conversely, the typical harsh
ejection systolic murmur at the right second intercostal
space that radiate to the carotid arteries may peak early

October 2000

194

CARDIOVASCULAR DISEASES IN THE ELDERLY

and the intensity of the aortic second sound may not be
markedly reduced, leading to the underestimation of
the severity.130 In addition, a plateau pulse may not be
obvious even in severe aortic stenosis. There may be
accompanied signs of pressure overloading apical
impulse due to LVH, and co-existing aortic regurgitation
murmur. Occasionally patients may present with
complication of aortic stenosis such as heart failure or
infective endocarditis.

Diagnosis and Treatment
With the use of Doppler echocardiography, the
need for invasive investigation is largely obviated except
for those with severe disease in whom surgery is
considered. Doppler echocardiography can accurately
estimate transvalvular pressure gradient and aortic valve
area. In addition, patients might have left ventricular
hypertrophy in ECG and cardiomegaly in chest
roentgenography. Because of the relatively high surgical
mortality of aortic valve replacement in geriatric
patients, patients who are asymptomatic even with
severe aortic stenosis should probably be treated
conservatively with close clinical monitoring. 131
However, those with symptoms of angina, dyspnoea and
syncopy should be evaluated for considering surgery
and CABG should coronary artery disease is detected
by coronary angiography. Since the presence of left
ventricular systolic dysfunction is the most important
predictor of mortality in elderly undergoing aortic
valvular replacement, surgery should therefore be
performed before there is any significant cardiac
decompensation. 132 Both open and close aortic
valvotomy had disappointing results because of
restenosis. Percutaneous balloon aortic valvuloplasty
has acute success with improvement in leaflet mobility
and orifice area, though the vascular complication rate
is as high as 15% 133 and the long-term result is
unsatisfactory with late death reported in nearly onethird of patients.134 Therefore this procedure is used for
palliation of symptoms for those who has poor surgical
risk due to co-morbidities.

Aortic Regurgitation
Although severe aortic regurgitation is
uncommon in the elderly, some degree of aortic
regurgitation is prevalent.135 In this age group, aortic
root dilatation is the predominant cause. Other causes
include chronic rheumatic heart disease, myxomatous
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degeneration, seropositive and seronegative arthritis.
Although in most cases no underlying cause is found,
aortic regurgitation is associated with hypertension
in about 10% of patients, which is usually mild in
severity.136

Clinical Features
Usually elderly patients are presented with
chronic aortic regurgitation, though occasionally acute
presentation can be due to infective endocarditis or
associated with aortic dissection. The majority of
patients with chronic disease are asymptomatic.
Occasionally there are symptoms of palpitation, fatigue
or angina. Examination will reveal a wide pulse
pressure, displaced apical impulse, and a high pitch early
diastolic decrescendo murmur over the sternal border.
Severe aortic regurgitation may give rise to peripheral
signs of hyperdynamic circulation such as Corrigan sign
and pistol-shot femoral. A systolic murmur, long
diastolic murmur, the presence of Austin-Flint murmur,
or occurrence of third heart sound will signify significant
aortic regurgitation.

Diagnosis and Treatment
The most useful investigation is probably the use
of Doppler echocardiography. The visualisation of
valvular anatomy allows the differentiation of aortic root
dilatation from valvular cause of aortic regurgitation.
Methods used to assess the severity include the reversal
of thoracic aortic flow,137 presystolic mitral valve closure
or mitral regurgitation, a short aortic pressure halftime, 138 and a large ratio of regurgitant jet to left
ventricular outflow tract width. 139 An integrated
approach by a combination of various Doppler
echocardiographic parameters has also been described
recently.140 The treatment of chronic aortic regurgitation
is usually medical, which comprise the use of
vasodilators to decrease the afterload of the heart such
as hydralazine, calcium channel blocker and ACEI.141
The use of ACEI has also been shown to regress LVH
associated with volume overload. 142 The use of
nifedipine has been shown to be able to improve cardiac
output and reduces the need for aortic valve
replacement.143,144 Patients with mild to moderate aortic
regurgitation usually have a good long-term prognosis,
with a 10-year survival rate of about 90%.145 Patients
with severe aortic regurgitation should be closely
monitored and aortic valve replacement considered shall
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they develop symptoms of exercise intolerance or
progressive left ventricular dilatation which herald the
onset of left ventricular systolic dysfunction. It has been
reported that elderly patients stand a higher risk of
mortality for aortic valve replacement than younger
subjects.146

Hypertension
Hypertension is more than a disease of ageing.
The detrimental cardiovascular effect of high blood
pressure such as myocardial infarction, heart failure and
stroke is more prevalent in elderly hypertensives. In
Framingham study the cardiovascular event risk is at
least twice higher in those older than 65 year-old
hypertensives than the younger subjects. 147 The
prevalence of hypertension in the older population varies
according to the definition. For a commonly used blood
pressure cut-off of 160/95 mmHg, the prevalence is 30%
in elderly men, and an additional 10-15% of total elderly
population have isolated systolic hypertension.148

Clinical Features
In general the clinical features of hypertension
in elderly are similar to young adults. However, one
should aware of the existence of generalised
atherosclerosis in elderly who may present with
accompanying symptoms, such as acute pulmonary
oedema in bilateral atherosclerotic renal artery stenosis
who are previously asymptomatic. In addition,
hypertensive complications are common presentation,
such as congestive heart failure which can be due to
diastolic dysfunction or pump failure,25,149 and acute
myocardial infarction. Since blood pressure in elderly
is more labile than in the middle age, it should be
measured repeatedly (at least in three different
occasions) and in different postures (sitting and
standing) in order to establish a baseline value for the
diagnosis.150 As secondary cause of hypertension is less
likely, the investigation is usually directed towards the
detection of cardiovascular complications caused by
atherosclerosis such as carotid stenosis, ischaemic heart
disease and renal artery stenosis when bruits are heard.

Management
In the management of hypertension, medical
therapy for optimal blood pressure control remains the
main goal. It is imperative to achieve a satisfactory blood
pressure level as it is closely related to complication
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rate. A few clinical trials addressed the importance of
drug treatment in elderly hypertensives. In Veterans
Administration Study, medical treatment of patients
aged 60 years or above significantly decreased
cardiovascular events by 54% when compared to
placebo. 151 Similarly, in Australian National Blood
Pressure Study, treatment of patients aged 60 to 69 years
reduced fatal and non-fatal cardiovascular events by
36%, although in significant.152 Another trial which
specifically conducted to assess the effect of
antihypertensive therapy in 840 elderly found that the
5-year cardiac mortality was significantly decreased by
47% when compared with placebo, although the allcause mortality was insignificantly reduced by 26%.153
In another clinical trial comparing routine and
intensified antihypertensive treatment, there was a 16%
reduction in all-cause mortality in elderly age group.154
Other investigators also reported a decrease in incidence
of stroke. 155 The Hypertension Optimal Treatment
addressed the medical treatment of hypertensive adults
aged from 50 to 80 years that the optimal systolic and
diastolic blood pressure for lowest cardiovascular
mortality was 138.8 and 86.5mmHg respectively.156
The choice of antihypertensive agents in the
elderly are not much different from the usual guideline,
though one should aware of the higher vulnerability of
side effects. Some patients may respond to monotherapy
though it might be necessary to use combination of
different agents for optimal blood pressure control as
well as minimising the side effect of individual agent.
Thiazide diuretics and β-blockers are commonly
prescribed as first line agents.157 For the former, potential
risk of cardiac arrhythmia due to hypokalaemia should
be alerted especially in those with co-existing LVH.158
Regular monitoring of plasma electrolytes and adding
a potassium-spearing diuretics is recommended.
Although diuretics may adversely affect lipid profile,
the effect is small and easily corrected with a diet low
in cholesterol. The use of low dose diuretics (with
potassium sparing) has been proven to reduce both
stroke and myocardial infarction in the elderly.159 Betablocker is advantageous in patients with accompanying
ischaemic heart disease, though it should be avoided in
those with peripheral vascular disease and chronic
obstructive pulmonary disease. The theoretical
disadvantage of decreased responsiveness and
tolerability to β-blockers in relation to ageing has not
been confirmed to have clinical significance.160 The use
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of newer agents for hypertensive control is gaining
increasing popularity, namely ACEI, calcium channel
blocker and AIIA. Despite having a lower plasma level
of renin activity in the elderly than younger individuals,
elderly patients respond equally well to these agents as
evident by post-marketing surveillance studies.161,162 The
occurrence of side effect is also non age-dependent.163
For the use of ACEI, long-acting ones are now in favour
because of the higher trough to peak ratio, which should
confer better blood pressure lowering effect. In the
elderly, the use of ACEI may increase the susceptibility
to orthostatic hypotension.52 They are also having a
higher risk of first-dose hypotension especially in the
presence of risk factors such as renal impairment,
hyponatraemia, low plasma volume or receiving high
dose diuretic treatment. This can be alleviated by the
use of longer-acting ACEIs. 164 In addition, the preexisting or new occurrence of renal dysfunction should
alert the possibility of renal artery stenosis. ACEI is
preferred in patients with co-existing congestive heart
failure, though it should be introduced even more
cautiously with a lower initial dosage. The use of AIIA
has been proven to be safe and effective in elderly
hypertensives, and first-dose hypotension seems not a
problem.165 However, long term tolerability studies are
needed. A large, prospective, randomised clinical trial
is underway to compare ACEI and diuretic therapy in
the reduction of cardiovascular events in elderly
hypertensive subjects.166 The use of calcium channel
blocker in elderly is at least as effective as in younger
hypertensive patients. 167 Compliance of medical
treatment is a potential problem in the elderly and
therefore medical regimens should be as simple as
possible.

Atrial Fibrillation
Atrial fibrillation (AF) is the commonest cardiac
arrhythmia in clinical practice. Its prevalence doubles
with each advancing decade of age, from 0.5% at 5059 years to nearly 9% at 80-89 years.168 Also, the disease
is more prevalent nowadays than 30 years ago when
comparing patients of similar age groups,168 and is
present in 2% of an elderly population low in the
incidence of coronary artery disease.169 In the follow
up of Framingham heart study, people who subsequently
developed AF had increased risk of mortality, which is
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1.5 and 1.9 fold in men and women respectively.170 In
contrary to the young adults in whom lone AF is more
common, elderly patients develop AF usually secondary
to cardiac disease, namely ischaemic heart disease,
hypertension, sick sinus syndrome and various
cardiomyopathies.171 Not uncommonly, the occurrence
of AF in the elderly is secondary to cardiac surgery,
such as bypass surgery and valvular replacement, and
non-cardiac conditions, such as pneumonia,
thyrotoxicosis, major pulmonary embolism, diabetes
and alcoholism. The Framingham heart study found that
AF developed in 12% of population aged 28 to 62 years
after 40 years of follow-up.170
From the duration and electrical behaviour of AF,
it can be divided into recent onset and chronic ones.
The chronic AF can be further classified into
paroxysmal AF (converted spontaneously), persistent
AF that required medical or electrical cardioversion,
and permanent AF which refers to those either unable
or have a low chance to be converted back to sinus
rhythm by any means.

Clinical Features
Patients with AF usually have symptoms of
palpitation, dyspnoea and impaired exercise
tolerance. 172 The symptoms of decompensation is
particularly obvious in advance age who depends more
on the normal atrial kick to maintain an adequate
diastolic filling. In acute onset and paroxysmal AF,
symptoms may be less well tolerated than in chronic
AF. The occurrence of acute AF in elderly can be a
manifestation of underlie condition which should be
investigated vigorously, such as thyrotoxicosis and
pulmonary embolism. When there is a fast ventricular
response, the risk of developing cardiac failure is
increased, especially those with underlie structural
cardiac disease such as old myocardial infarction and
LVH. AF is also associated with tachycardia-induced
cardiomyopathy and the irregular ventricular rate
itself also predispose to the development of cardiac
failure.173,174 The other major complication of AF which
resulting in morbidity and mortality is related to
thromboembolism, especially stroke. The risk of stroke
is increased by five- and seventeen-fold in nonrheumatic and rheumatic AF respectively. Age is
another independent risk factor, and the stroke incidence
in lone AF increases from 1.6% to 3% during the seventh
to ninth decades of life.175 Other risk factors for stroke
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in AF include cardiac failure, symptomatic ischaemic
heart disease, hypertension, diabetes, and importantly,
previous stroke or transient ischaemic attack.176 The
occurrence of atrial thrombosis is likely related to atrial
mechanical dysfunction (atrial stunning) 177,178 and
possibly a hypercoagulable state due to activation
of platelets or components of the coagulation
cascade.179,180

Management
The management principles of AF include
treatment of precipitating factors, restoration of sinus
rhythm, rate control and anticoagulation prophylaxis.
Restoration of sinus rhythm should be the primary goal
since cardiac function (heart rate, diastolic filling and
systolic function) can be normalised, while
thromboembolic complication and side effect of antiarrhythmic medication can be avoided. Cardioversion
should be considered for every patients where possible.
Synchronised electrical DC cardioversion is the choice
for those with haemodynamic compromise. Apart from
the conventionally used transthoracic external shock,
internal defibrillation by transvenous catheter using lowenergy shock is also performed by some centres.
Pharmacological cardioversion is less effective than
electrical cardioversion, though it obviates the need for
sedation. The choice of drugs include class Ic
(propaferone, flecanide), class III (amiodarone, sotalol,
ibutilide) and class Ia agents (quinidine). For patients
with impaired left ventricular function on
echocardiography, amiodarone will be a better choice
by virtue of its devoid of negative inotropic effect. For
a AF duration of 48 hours or longer, anticoagulation
should be started for 3 weeks before cardioversion, and
at least for another 4 weeks after the procedure to
minimise the risk of thromboembolism. However, atrial
thrombi had been reported in acute AF of less than 3
days.181 In the situation where emergency cardioversion
is contemplated, intravenous heparin should be given
to cover the procedure. Some centres might perform
transoesophageal echocardiography to confirm the
absence of atrial appendage thrombi before
cardioversion in place of coumardin pre-treatment.182
New development include the use of implantable device
for internal fibrillation183,184 and transvenous catheter
ablation for focal atrial fibrillation.185,186 Patients with
persistent AF may also benefit from surgical procedures
such as Corridor or Maze operation, which has been
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shown to be possible to restore sinus rhythm even in
those with giant left atrium. 187 However, these
procedures are associated with significant morbidity and
mortality, and are at present used in a handful of patients
in specialised centres.
The aim of rate control is to minimise symptom
related to fast ventricular response for those suffering
from permanent or paroxysmal AF. The potential
difference of outcomes of this approach versus rhythm
c o n t r o l i s c u r r e n t l y u n d e r i n v e s t i g a t i o n . 188
Pharmacological therapy of choice include β-blockers,
calcium channel blockers in the phenylalkylamine
(e.g. verapramil) and benzothiazepine (e.g. diltiazem)
classes and digoxin. The latter agent has less effect in
exercise-induced tachycardia, though its inotropic effect
will favour the use in heart failure. More invasive
therapy will be reserved for medically resistant AF. This
includes the use of catheter-based atrioventricular
modification or ablation with pacemaker
implantation.189,190
Aspirin has been used as prophylaxis for
thromboembolism for younger patients with lone AF.
However, patients at higher risk of thromboembolism
should be anticoagulated with warfarin, including
elderly age itself. The benefit of warfarin in the
prevention of stroke outweighs the risk of haemorrhage
and should be considered in elderly unless
contraindicated.191 The use of warfarin has also been
reported to reduce silent cerebral infarction in elderly
patients with atrial fibrillation.192 Indeed, it was found
that anticoagulation therapy was underutilised in elderly
and a study found a anticoagulation rate of only about
50% of eligible patients.193 However, elderly might need
more close monitoring of their INR in order to avoid
over-anticoagulation and its associated higher
haemorrhagic risk.194 The fact that Chinese ethnics and
elderly age require a lower maintenance dose also need
to be entertained.195

Conclusion
Cardiovascular diseases are more common in the
elderly population, primarily lots of these conditions
are degenerative in nature, together with increases in
risk factors of diseases. Management of these diseases
in elderly can be different from younger patients, and
special focus should be put onto the effect of ageing on
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the pharmacokinetics and pharmacodynamis of
medication, the overall medical and physical condition
as well as co-existence of other organ dysfunction. On
the other hand, standard therapy should not be limited
because of age alone, which could involve invasive
investigation and aggressive treatment modalities.
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